Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Using prognosis to guide … - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Using prognosis to guide inclusion criteria, define standardised endpoints and stratify follow-up in active surveillance for prostate cancer

Artikel i vetenskaplig tidskrift
Författare V. J. Gnanapragasam
T. Barrett
V. Thankapannair
D. Thurtle
J. Rubio-Briones
J. Domínguez-Escrig
Ola Bratt
P. Statin
K. Muir
A. Lophatananon
Publicerad i Bju International
Volym 124
Nummer/häfte 5
Sidor 758-767
ISSN 1464-4096
Publiceringsår 2019
Publicerad vid Institutionen för kliniska vetenskaper
Sidor 758-767
Språk en
Länkar dx.doi.org/10.1111/bju.14800
Ämnesord #PCSM, #ProstateCancer, Active surveillance, Cambridge Prognostic Groups, Intermediate-risk, Localised prostate cancer, Low-risk, Stratified follow-up
Ämneskategorier Cancer och onkologi, Urologi och njurmedicin

Sammanfattning

Objectives: To test whether using disease prognosis can inform a rational approach to active surveillance (AS) for early prostate cancer. Patients and methods: We previously developed the Cambridge Prognostics Groups (CPG) classification, a five-tiered model that uses prostate-specific antigen (PSA), Grade Group and Stage to predict cancer survival outcomes. We applied the CPG model to a UK and a Swedish prostate cancer cohort to test differences in prostate cancer mortality (PCM) in men managed conservatively or by upfront treatment in CPG2 and 3 (which subdivides the intermediate-risk classification) vs CPG1 (low-risk). We then applied the CPG model to a contemporary UK AS cohort, which was optimally characterised at baseline for disease burden, to identify predictors of true prognostic progression. Results were re-tested in an external AS cohort from Spain. Results: In a UK cohort (n = 3659) the 10-year PCM was 2.3% in CPG1, 1.5%/3.5% in treated/untreated CPG2, and 1.9%/8.6% in treated/untreated CPG3. In the Swedish cohort (n = 27 942) the10-year PCM was 1.0% in CPG1, 2.2%/2.7% in treated/untreated CPG2, and 6.1%/12.5% in treated/untreated CPG3. We then tested using progression to CPG3 as a hard endpoint in a modern AS cohort (n = 133). During follow-up (median 3.5 years) only 6% (eight of 133) progressed to CPG3. Predictors of progression were a PSA density ≥0.15 ng/mL/mL and CPG2 at diagnosis. Progression occurred in 1%, 8% and 21% of men with neither factor, only one, or both, respectively. In an independent Spanish AS cohort (n = 143) the corresponding rates were 3%, 10% and 14%, respectively. Conclusion: Using disease prognosis allows a rational approach to inclusion criteria, discontinuation triggers and risk-stratified management in AS. © 2019 The Authors. BJU International © 2019 BJU International Published by John Wiley & Sons Ltd

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?